Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc. is demonstrating encouraging progress in its clinical development, particularly with its lead candidate, vidofludimus calcium, for the treatment of relapsing multiple sclerosis (RMS), supported by positive results from the Phase 2 CALLIPER and EMPhASIS trials that indicate reductions in disability worsening and improved safety profiles. The additional data underscores the drug's potential neuroprotective effects and anti-viral activity against chronic EBV infection, which is believed to influence disease progression in MS patients. As the company advances into pivotal trials for RMS, these promising findings contribute to a favorable outlook on Immunic's stock performance, reflecting the strength of its pipeline in addressing chronic inflammatory and autoimmune diseases.

Bears say

Immunic Inc. is experiencing significant financial challenges that contribute to a negative outlook on its stock. The company has recently faced a decrease in the effectiveness of its leading treatment candidates, as evidenced by the drop in gadolinium-enhancing lesions in patients receiving vidofludimuscalcium, which suggests potential issues in achieving commercial success. Additionally, the company continues to incur substantial operating losses, with quarterly expenses totaling $26 million juxtaposed against a backdrop of limited capital resources and a recent downward revision of price targets, raising concerns about its ability to fund ongoing operations and development.

Immunic Inc (IMUX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.